Cargando…
Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
OBJECTIVE: To analyze comparative treatment persistence for first‐line baricitinib (BARI) versus first‐line tumor necrosis factor inhibitor (TNFi) in patients with rheumatoid arthritis (RA) and for first‐line BARI initiated as monotherapy versus first‐line BARI initiated with at least one convention...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349226/ https://www.ncbi.nlm.nih.gov/pubmed/37308464 http://dx.doi.org/10.1002/acr2.11577 |
_version_ | 1785073857369997312 |
---|---|
author | Ciciriello, Sabina Littlejohn, Geoffrey Treuer, Tamas Gibson, Kathryn A. Haladyj, Ewa Youssef, Peter Bird, Paul O'Sullivan, Catherine Smith, Tegan Deakin, Claire T. |
author_facet | Ciciriello, Sabina Littlejohn, Geoffrey Treuer, Tamas Gibson, Kathryn A. Haladyj, Ewa Youssef, Peter Bird, Paul O'Sullivan, Catherine Smith, Tegan Deakin, Claire T. |
author_sort | Ciciriello, Sabina |
collection | PubMed |
description | OBJECTIVE: To analyze comparative treatment persistence for first‐line baricitinib (BARI) versus first‐line tumor necrosis factor inhibitor (TNFi) in patients with rheumatoid arthritis (RA) and for first‐line BARI initiated as monotherapy versus first‐line BARI initiated with at least one conventional synthetic disease‐modifying antirheumatic drug (csDMARD). METHODS: Patients with RA who initiated BARI or TNFi as first‐line biologic or targeted synthetic DMARD from October 1, 2015, to September 30, 2021, were identified in the OPAL data set. Drug survival times to 6, 12, and 24 months were analyzed using restricted mean survival time (RMST). Multiple imputation and inverse probability of treatment weighting were used to address missing data and nonrandom treatment assignment. RESULTS: A total of 545 patients initiated first‐line BARI, including 118 as monotherapy and 427 as csDMARD combination therapy. Three thousand five hundred patients initiated first‐line TNFi. There was no difference in drug survival to 6 or 12 months for BARI compared with TNFi; differences in RMST were 0.02 months (95% CI: −0.08 to 0.013; P = 0.65) and 0.31 months (95% CI: −0.02 to 0.63; P = 0.06), respectively. Patients in the BARI group had 1.00 month (95% CI: 0.14 to 1.86; P = 0.02) longer drug survival to 24 months. There was no difference in drug survival for BARI monotherapy compared with combination therapy, with differences in RMST to 6, 12, and 24 months of −0.19 months (95% CI: −0.50 to 0.12; P = 0.12), −0.35 months (95% CI: −1.17 to 0.42; P = 0.41), and −0.56 months (95% CI: −2.66 to 1.54; P = 0.60), respectively. CONCLUSION: In this comparative analysis, treatment persistence up to 24 months was significantly longer for first‐line BARI compared with TNFi, but the effect size of 1.00 month is not clinically meaningful. There was no difference in persistence for BARI monotherapy versus combination therapy. |
format | Online Article Text |
id | pubmed-10349226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wiley Periodicals, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103492262023-07-16 Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set Ciciriello, Sabina Littlejohn, Geoffrey Treuer, Tamas Gibson, Kathryn A. Haladyj, Ewa Youssef, Peter Bird, Paul O'Sullivan, Catherine Smith, Tegan Deakin, Claire T. ACR Open Rheumatol Original Articles OBJECTIVE: To analyze comparative treatment persistence for first‐line baricitinib (BARI) versus first‐line tumor necrosis factor inhibitor (TNFi) in patients with rheumatoid arthritis (RA) and for first‐line BARI initiated as monotherapy versus first‐line BARI initiated with at least one conventional synthetic disease‐modifying antirheumatic drug (csDMARD). METHODS: Patients with RA who initiated BARI or TNFi as first‐line biologic or targeted synthetic DMARD from October 1, 2015, to September 30, 2021, were identified in the OPAL data set. Drug survival times to 6, 12, and 24 months were analyzed using restricted mean survival time (RMST). Multiple imputation and inverse probability of treatment weighting were used to address missing data and nonrandom treatment assignment. RESULTS: A total of 545 patients initiated first‐line BARI, including 118 as monotherapy and 427 as csDMARD combination therapy. Three thousand five hundred patients initiated first‐line TNFi. There was no difference in drug survival to 6 or 12 months for BARI compared with TNFi; differences in RMST were 0.02 months (95% CI: −0.08 to 0.013; P = 0.65) and 0.31 months (95% CI: −0.02 to 0.63; P = 0.06), respectively. Patients in the BARI group had 1.00 month (95% CI: 0.14 to 1.86; P = 0.02) longer drug survival to 24 months. There was no difference in drug survival for BARI monotherapy compared with combination therapy, with differences in RMST to 6, 12, and 24 months of −0.19 months (95% CI: −0.50 to 0.12; P = 0.12), −0.35 months (95% CI: −1.17 to 0.42; P = 0.41), and −0.56 months (95% CI: −2.66 to 1.54; P = 0.60), respectively. CONCLUSION: In this comparative analysis, treatment persistence up to 24 months was significantly longer for first‐line BARI compared with TNFi, but the effect size of 1.00 month is not clinically meaningful. There was no difference in persistence for BARI monotherapy versus combination therapy. Wiley Periodicals, Inc. 2023-06-12 /pmc/articles/PMC10349226/ /pubmed/37308464 http://dx.doi.org/10.1002/acr2.11577 Text en © 2023 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Ciciriello, Sabina Littlejohn, Geoffrey Treuer, Tamas Gibson, Kathryn A. Haladyj, Ewa Youssef, Peter Bird, Paul O'Sullivan, Catherine Smith, Tegan Deakin, Claire T. Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set |
title | Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set |
title_full | Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set |
title_fullStr | Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set |
title_full_unstemmed | Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set |
title_short | Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set |
title_sort | comparative effectiveness of first‐line baricitinib in patients with rheumatoid arthritis in the australian opal data set |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349226/ https://www.ncbi.nlm.nih.gov/pubmed/37308464 http://dx.doi.org/10.1002/acr2.11577 |
work_keys_str_mv | AT ciciriellosabina comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT littlejohngeoffrey comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT treuertamas comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT gibsonkathryna comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT haladyjewa comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT youssefpeter comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT birdpaul comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT osullivancatherine comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT smithtegan comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT deakinclairet comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset AT comparativeeffectivenessoffirstlinebaricitinibinpatientswithrheumatoidarthritisintheaustralianopaldataset |